KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential [Yahoo! Finance]
Kodiak Sciences Inc (KOD)
Last kodiak sciences inc earnings: 11/12 05:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
that the company has a major “turnaround story” in place for 2025. Kodiak has lately been garnering immense investor attention driven by the significant potential of its ongoing late-stage studies on the lead candidate, tarcocimab, for retinal disease indications and other pipeline programs. Tarcocimab, a novel anti-VEGF antibody biopolymer conjugate, is being developed for diabetic eye disease and wet age-related macular degeneration (wet AMD). In its report, Jefferies stated that at $7 per share ($400 million market cap), the stock price is greatly undervalued and set a target price of $20, translating to a market cap of more than $1 billion in 2025, ahead of phase III data readouts. By 2026, Jefferies projects the stock price to approach $30-$50 or $1.5-$3 billion in market cap. Let us dig deeper into the catalysts behind Jefferies' optimism regarding the growth of Kodiak Sciences in the near future. In late 2023, Kodiak rebooted the development program of tarcocimab follow
Show less
Read more
Impact Snapshot
Event Time:
KOD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KOD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KOD alerts
High impacting Kodiak Sciences Inc news events
Weekly update
A roundup of the hottest topics
KOD
News
- Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases [Yahoo! Finance]Yahoo! Finance
- Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic DiseasesPR Newswire
- Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Inc. (NASDAQ: KOD) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock.MarketBeat
- Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]Yahoo! Finance
KOD
Earnings
- 11/14/24 - Beat
KOD
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- KOD's page on the SEC website